Obesity has virtually tripled worldwide since 1975.
In 2019 alone, the World Health Organization classified 38 million children under 5 years old as overweight or obese.
More alarmingly, obesity has been dubbed as the “silent killer” because it is one of the leading factors that cause premature deaths.
In 2017, 4.7 million or 8% of global deaths were linked to this condition.
For context, the number of deaths caused by obesity is 4 times the fatality rate from road accidents and almost 5 times the number of those who died from HIV/AIDS.
Right now, 39% of adults across the globe are considered overweight and 13% are obese.
By 2030, nearly half the adult population of the United States is expected to be suffering from obesity.
Now, we might have the answer to this “silent killer:” CRISPR gene editing.
A recent Harvard study showed that CRISPR gene editing can be used to engineer cells to avoid weight gain and even potentially stop the onset of obesity-related diseases like diabetes.
The solution is straightforward.
The scientists will convert the body’s white fat, which is the “bad fat,” into brown fat or the "good fat.”
Brown fat is known as the healthy fat because it produces heat for the body by burning calories. Meanwhile, white fat tends to build up and leads to obesity.
Through CRISPR gene editing, the white fat is transformed into brown fat. This will then be burned by the body and used as an energy source, which can also result in weight loss.
So far, the technology proved to be successful in mice which were put on a high-fat diet.
What CRISPR targets is a gene for a protein called UCP1, which is distinctly found in brown fat.
The function of UCP1 is to turn chemical energy into heat.
Using the UCP1, the researchers created cells that closely resembled brown fat cells. These are called human brown-like cells or HUMBLE cells.
The manufactured HUMBLE cells are then transplanted into the mice with weakened immune systems. These mice were also fed with a high-fat diet.
Upon observation, they found that the modified cells actively helped in preventing the progression of obesity in mice and even showed improvements in the metabolic function of the animals.
Over the course of 12 weeks, the mice given white fat cells continued to gain weight while those transplanted with the HUMBLE cells showed weight loss. The latter also showed higher sensitivity to insulin, indicating that they could be protected against diabetes.
This is where it gets interesting because the technique can ultimately lead to cell therapies not only for obesity but also other metabolic disorders.
In the future, the process could evolve into something as convenient as removing a small amount of a patient’s white fat and having that engineered into brown-like fat and re-implanted to the same person’s body.
Apart from that, the HUMBLE cells also appear to send a chemical trigger to the existing brown fat stored in the mice’s own bodies, stimulating them to burn more energy.
This means that a simpler treatment method could be explored in which the experts could mimic the signal to activate the patient’s own brown fat. This will no longer require re-engineering the white fat and re-implanting it, making the entire treatment extremely straightforward.
The release of this study has profound implications to the total available market for CRISPR gene editing technology.
In the US alone, over 34 million are suffering from diabetes. The medical spending and loss of work wages linked to this is valued at roughly $327 billion annually.
If this technology proves to be effective in boosting a patient’s insulin sensitivity, then it could open an exponentially huge market.
Aside from diabetes, obesity is also considered a major risk factor in certain types of cancer, fatty liver and kidney disease, osteoarthritis, and even pregnancy problems.
This study is another example of how gene editing can be utilized to find treatments for untreatable conditions in the past years.
With this groundbreaking potential, it is no wonder investors are lining up to get their hands in biotechnology stocks in the gene editing sector.
The most widely known gene editing stock is CRISPR Therapeutics (CRSP).
With a market capitalization of $5.72 billion, this company is the only one in its field with actual treatments set for launch in the market soon.
One is a rare genetic disease treatment called CTX-001. Every year, about 60,000 people are born with this condition, causing anemia, lifelong pain, and early death. The other treatment is CTX-100, which is geared towards cancer patients.
Compared to its competitors like Editas Medicine (EDIT), which has a market capitalization of $1.82 billion, and Intellia Therapeutics (NTLA) with $1.03 billion, CRSP has a financial runway that can be reassuring to its investors.
CRSP also has minimal debt and a beneficial partnership with healthcare giant Vertex Pharmaceuticals (VRTX). This makes it one of the most attractive gene editing stocks out today.
Nonetheless, buying early stage companies, especially in the biotechnology sector, can be like oil wildcatting back in the 1930s. The key is to spread your bets broad enough to boost your chances of finding a gusher.
If this CRISPR gene editing technology works to treat obesity and even diabetes, then it could revolutionize the medical field.
While it’s still wise to exercise caution when investing in gene editing stocks, this technology undoubtedly embodies how the future of medicine looks like.
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png00Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-09-10 14:00:312020-09-11 23:54:25Can CRISPR Stop the Silent Killer?
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline.Read more
https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg135150Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-09-10 11:08:532020-09-10 11:08:53Trade Alert - (TLT) September 10, 2020 - SELL-TAKE PROFITS
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline.Read more
https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg135150Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-09-10 10:52:472020-09-10 10:52:47Trade Alert - (TLT) September 10, 2020 - SELL-TAKE PROFITS
While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points.Read more
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png00Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-09-10 09:39:412020-09-10 09:39:41September 10, 2020 - MDT Pro Tips
Softbank’s CEO Masayoshi Son is playing with fire by snapping up more than $50 billion of call option exposure.
These call options are directly targeted at tech stocks which Son has an absolute fascination with.
The heavy purchasing of stock options has been the main catalyst in tech stock’s heading into bubble territory pushing prices up to outrageous highs.
Cornering the options market could lead to Softbank taking major write-downs if this high-risk strategy blows up in their face.
Remember that markets usually fall at a faster pace than vice-versa because of the nature of liquidity drying up and an avalanche of forced selling through stop-losses orders.
To add fuel to the fire, we have the U.S. Central Bank that is creating a false sense of security by buying junk bonds and supporting asset prices with broad-based asset purchases, and the lack of real opportunities in the tech market is forcing traders to leverage up multiple times just to spin a profit.
This all sounds eerily similar to Long-Term Capital Management L.P. (LTCM), doesn’t it?
Call option bets on technology stocks are now the narrative driving the broader market as we are unequivocally detached from reality at this point.
A worst-case scenario is a full-fledged rise in the systemic risk if a sell-off, which we are in the midst of, triggers a nasty and chaotic unwinding of bullish positions with indiscriminate selling.
The revealing of Softbank’s high stakes strategy appears to be the variable rocking the market.
Once these call options are deployed, Softbank is out of bullets and there is no incremental amount of capital to support the next leg up, meaning a “taking profits” pivot is the next order on the menu.
I believe regulators will take a look at the recent price action with Tesla at one point rising 75% in the past month alone. Are U.S. regulators prepared for the new normal to allow tech stocks like Amazon to rise 40% per day or drop 80% in one day? Markets cannot function with that level of volatility.
Clearly, Softbank’s heft in trading is moving markets and almost to the point of market manipulation which is cause for another concern.
The point is that this isn’t sustainable and the coming fall after unrealized gains are all taken off the table could slam the market with volatility so bad that it will make the 2008 recession look like a 1% pullback.
It is hard to know where this finally ends as the Fed is implicitly funding cheap money strategies that allow hedge funds to bet the ranch.
Now, this is bet the ranch and multiply that by ten. That’s the feeling I am getting from the price action lately.
Are we heading into hedge funds borrowing trillions of dollars and putting on 10s of trillions in highly leveraged directional bets?
That’s a scary thought.
If the brazenness gets to that level, it could finally be the straw that broke the camel's back for the U.S. financial system.
At the bare minimum, that day is certainly creeping closer.
One thing I can tell you is that Japanese investors are scared to death with these revelations.
Softbank is a massive conglomerate in Japan with many retail traders owning pieces of it.
Granted, Softbank could make it out of this with $10 billion in profits, but could also lose more than that and become a system risk in the Japanese financial system.
If it is found out that there are multiple hedge funds mimicking Softbank’s tens of billions call options strategy, we are headed into the eye of the storm and volatility is about to shoot through the roof.
Traders who aren’t used to 10% swings in daily pricing should sit this one out on the sidelines for the time being.
Yesterday alone, Softbank took a $10 billion loss on their positions.
Each day, Son’s nerves must be jangling.
Only he and his confidantes know the math of the positions, but if big losses mount, it could force him to cut losses if equity markets keep crashing.
The knock-on effects could be contagion around other parts of the global markets catalyzing yet another financial crisis on top of the current economic crisis.
Is the incremental trader willing to help out Son’s bet by buying the dip?
I would say the recent volatility should scare away traders in the short term boding ill for Softbank. The plain the vanilla buy the dip strategy is looking tenuous at best these days.
Where did this out of the blue trading strategy come from?
The company has recently indicated investing in U.S. markets: SoftBank announced in August that it would start a new unit for public investments with $555 million in capital.
The purchases are also notable given how much cash SoftBank has been raising this year. Last month, the company announced that it would sell more than one million shares in its Japanese mobile carrier affiliate SoftBank Corp., worth 1.47 trillion yen (nearly $14 billion) signaling this wave of call option buying has been in the works for a while.
That asset sale came on top of plans the firm announced in March to raise some 4.5 trillion yen ($42 billion) by selling assets.
SoftBank said last month that it believed it was "necessary to expand cash reserves ... to ensure flexible options to respond to changes in the market environment."
Prior to Monday's fall, SoftBank's stock was up about a third this year. It was a stunning turnaround for the company, which was embarrassed by a massive write-down on the disastrous WeWork bet last year.
This appears to be revenge and redemption wrapped into one.
In May, SoftBank reported an annual operating loss of 1.36 trillion yen ($12.7 billion) driven by massive write-downs in the Vision Fund.
What a world we live in!
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png00Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-09-09 10:02:022020-09-09 19:16:01What's Driving the Nasdaq?
“Don't chase a girl, let the girl chase you.” – Said Founder and CEO of Softbank Masayoshi Son
https://www.madhedgefundtrader.com/wp-content/uploads/2020/09/masayoshi-son.png252272Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-09-09 10:00:002020-09-09 11:29:50September 9,2020 - Quote of the Day
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.